Tesamorelin TSM
GHRH analogue
Synthetic 44-amino-acid GHRH analogue, stabilised by an N-terminal trans-3-hexenoyl group, that stimulates pituitary growth hormone release.
Evidence level. Published human clinical data exists, from trials or approved use. About the badges
- Class
- GHRH analogue
- Category
- Growth Hormone Axis
- Type
- Single compound
- Abbreviation
- TSM
- Development and regulatory status
- Approved prescription drug (HIV-associated abdominal lipodystrophy)
What researchers study
Synthetic 44-amino-acid analogue of human GHRH carrying an N-terminal trans-3-hexenoyl group that slows enzymatic breakdown. It stimulates pituitary growth hormone release and raises IGF-I.
Research areas
- GH axis and visceral-fat metabolism models
- Hepatic fat and liver-enzyme studies in HIV cohorts
- Muscle density and body-composition analyses
- GHRH receptor pharmacology
Reported findings
Summaries of published results. Each one is tagged with the type of study behind it. They describe research outcomes and are not claims about any product. Why study type matters.
- phase 3 trial
In 412 adults with HIV and abdominal fat, 26 weeks of tesamorelin reduced visceral fat by 15.2% versus a 5.0% rise with placebo
- human trial
A pooled analysis of two phase 3 trials (806 adults with HIV) linked visceral-fat reduction with greater falls in ALT and AST
- review
A meta-analysis of four randomised trials (909 patients) reported reduced visceral fat and waist circumference, with limited long-term safety data
Studied alongside
Compounds that appear together in research because their mechanisms complement each other, or as comparators. The reasons given are research reasoning, not recommendations for use.
- Ipamorelinghrelin-receptor agonist studied with GHRH analogues for combined GH release
- Tesamorelin + Ipamorelinresearch blend of the two peptides
- AOD9604GH fragment studied for fat-metabolism endpoints with a different mechanism
- CJC-1295 (no DAC)alternative GHRH analogue used for comparison
